Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,994
Total Claims
$5.4M
Drug Cost
718
Beneficiaries
$7,565
Cost/Patient
Risk Score Breakdown 16/100
Score components are additive. Read full methodology
Peer Comparison vs. 218,535 Nurse Practitioner providers
+544%
Cost per patient vs peers
$7,565 vs $1,174 avg
+658%
Brand preference vs peers
67.2% vs 8.9% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
🔎 Data Overview
Cost per patient is 544% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Brand vs Generic
Brand: 5,301 claims · $5.3M
Generic: 2,586 claims · $37K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 832 | $1.1M |
| Empagliflozin | 591 | $519K |
| Insulin Aspart | 312 | $362K |
| Insulin Glargine,hum.Rec.Anlog | 475 | $348K |
| Dulaglutide | 288 | $333K |
| Insulin Regular, Human | 192 | $326K |
| Insulin Lispro | 170 | $191K |
| Insulin Detemir | 182 | $155K |
| Sitagliptin Phosphate | 146 | $109K |
| Insulin Degludec | 134 | $101K |
| Insulin Lispro | 53 | $97K |
| Insulin Aspart | 93 | $87K |
| Linagliptin | 140 | $87K |
| Teriparatide | 19 | $81K |
| Insulin Nph Hum/Reg Insulin Hm | 81 | $79K |
Prescribing Profile
Patient Profile
70
Avg Age
53%
Female
1.86
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data